Anti-cancer-associated non-tumor cell agent comprising virus

A method for damaging a cancer-associated non-tumor cell, comprising:

• administering to a subject an anti-cancer-associated non-tumor cell agent comprising a recombinant virus comprising:
• a first gene cassette containing a telomerase reverse transcriptase promoter, an adenoviral E1A gene, an IRES sequence and an adenoviral E1B gene;
• and
• a second gene cassette containing a promoter and a p53 gene,
• wherein the virus is a recombinant adenovirus,
• wherein the second gene cassette further comprises a poly A sequence downstream of the promoter and the p53 gene, and
• wherein the recombinant adenovirus lacks an E1 region or the E1 region is partially deleted,
• wherein administering the agent treats and/or prevents a cancer by damaging cancer-associated non-tumor cells, and wherein the cancer is selected from the group consisting of pancreas cancer, lung cancer, liver cancer, prostate gland cancer, bladder cancer, gallbladder/biliary duct cancer, breast cancer, uterus cancer, thyroid gland cancer and ovary cancer.

A method for damaging a cancer-associated non-tumor cell, comprising:

• administering to a subject an anti-cancer-associated non-tumor cell agent comprising a recombinant virus comprising:
• a first gene cassette containing a telomerase reverse transcriptase promoter, an adenoviral E1A gene, an IRES sequence and an adenoviral E1B gene;
• and
• a second gene cassette containing a promoter and a p53 gene,
• wherein the virus is a recombinant adenovirus,
• wherein the second gene cassette further comprises a poly A sequence downstream of the promoter and the p53 gene, and
• wherein the recombinant adenovirus lacks an E1 region or the E1 region is partially deleted, wherein administering the agent treats and/or prevents a cancer or disease by damaging cancer-associated non-tumor cells, and wherein the cancer or disease is the cancer or disease in which the presence of CAFs is an impediment to treatment.